<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437538</url>
  </required_header>
  <id_info>
    <org_study_id>2017/830/1</org_study_id>
    <nct_id>NCT03437538</nct_id>
  </id_info>
  <brief_title>Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter</brief_title>
  <official_title>Reduction Ratio and Clearance of Middle Molecules During a Single Hemodialysis Session With Medium Cut-Off (MCO) Filter Compared to Hemodiafiltration (HDF) With Standard High-flux Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Medium Cut-Off dialysis (MCO) membrane has been developed to improve middle molecule
      removal compared to standard high-flux dialysis filters.

      The major aim of this study is to compare the reduction ratio and clearance of middle
      molecules, during a single hemodialysis session with MCO-filter, compared to
      hemodiafiltration (HDF) with standard high-flux filter.

      Secondary aims are to compare the reduction ratio and clearance of small and large molecules
      between the treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction ratio (RR) of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RR of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of adverse events during a 4h dialysis session</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <condition>Uremia</condition>
  <condition>Dialysis</condition>
  <arm_group>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with ongoing HDF-treatments (&gt;3months) will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with ongoing HDF-treatments (&gt;3months) will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MCO-HD</intervention_name>
    <description>Measurements will be done during a single hemodialysis session with Medium Cut-Off filter</description>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flux HDF</intervention_name>
    <description>Measurements will be done during a single hemodiafiltration session with standard high-flux filter</description>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ongoing HDF treatment (&gt;3 months)

          -  Albumin ≥ 30

          -  CRP &lt;15

          -  No Acute Myocardial Infarction within 3 months.

        Exclusion Criteria:

          -  Not able to understand the study information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Christensson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane, Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christensson</last_name>
    <phone>+46 40-3331559</phone>
    <email>anders.christensson@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christensson</last_name>
      <email>anders.christensson@med.lu.se</email>
    </contact>
    <contact_backup>
      <phone>+41 40-3331559</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>MCO</keyword>
  <keyword>Middle molecules</keyword>
  <keyword>High Retention Onset</keyword>
  <keyword>Medium Cut-Off</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

